Nasdaq · Healthcare

Janux Therapeutics, Inc. (JANX)

As-reported financials and recent SEC filings for Janux Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$10.0M

Net income

$-113.6M

Net margin

—

Diluted EPS

$-1.83

ROE

-11.9%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$10.0M	$10.6M	$8.1M	$8.6M	$3.6M
Gross profit	—	—	—	—	—
Operating income	$-157.7M	$-98.8M	$-73.0M	$-67.1M	$-32.9M
Net income	$-113.6M	$-69.0M	$-58.3M	$-63.1M	$-32.7M
Diluted EPS	$-1.83	$-1.28	$-1.32	$-1.52	$-1.39

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-06-23

42026-06-12

42026-06-12

42026-06-12

42026-06-12

42026-06-12

42026-06-12

42026-06-12

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on JANX

Search Janux Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.